Coverage dated November 3, 2025 to November 5, 2025
Trump unveils deal to expand coverage and lower costs on obesity drugs
Headline from The Columbian, on the newest of 2 developments
WASHINGTON — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.
The Columbian's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly
Headline from STAT ·
Newest
Trump unveils deal to expand coverage and lower costs on obesity drugs
Eli Lilly and Novo Nordisk are working with the Trump administration on a deal to cut weight loss drug costs to $149 monthly through the new TrumpRx initiative.
The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of their weight loss drugs, a person familiar with the plan said.
The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar with the negotiations.
WASHINGTON — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.
US President Donald Trump announced deals Thursday with pharmaceutical giants Eli Lilly and Novo Nordisk to lower the prices of some popular weight-loss drugs, in exchange for relief from threatened tariffs.
Novo Nordisk and Eli Lilly finalized a deal with the Trump Administration to reduce costs of Wegovy and Zepbound weight-loss drugs through the new TrumpRx program.
Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy; and Indianapolis-based Eli Lilly, which makes Zepbound, will agree to sell their drugs to Medicare at a lower "most favored nation" rate.
President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy